G Gahrton. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Aclarubicin/analogs & derivativesAcute DiseaseAdolescentAdultAge FactorsAminoacridines/therapeutic useAmsacrineAnthraquinones/therapeutic useAntibodies, MonoclonalAzacitidine/therapeutic useBone Marrow TransplantationChildChild, PreschoolDrug Administration ScheduleEtoposide/therapeutic useHumansIfosfamide/therapeutic useImmunotherapyInfantInterferons/therapeutic useLeukemia/mortalityLeukemia/therapyLeukemia, Lymphoid/therapyLiposomes/administration & dosageMiddle AgedMitoxantroneNaphthacenes/therapeutic usePrognosisTeniposide/therapeutic useTransplantation, HomologousTransplantation, IsogeneicVinblastine/analogs & derivativesVinblastine/therapeutic useVindesine
Substances: See more » AminoacridinesAnthraquinonesAntibodies, MonoclonalLiposomesNaphthacenesaclacinomycinsAmsacrineVinblastineEtoposideAclarubicinInterferonsTeniposideMitoxantroneAzacitidineVindesineIfosfamide
Year: 1983 PMID: 6197869 DOI: 10.1016/s0065-230x(08)60682-x
Source DB: PubMed Journal: Adv Cancer Res ISSN: 0065-230X Impact factor: 6.242